Bridget joined Nocion in August 2018, bringing over 20 years of experience advancing compounds from high-throughput screening through phase 2 clinical trials. Most recently, she was the Vice President of Medicinal Chemistry at Axial Biotherapeutics, where she developed microbiome-inspired therapies for the treatment of neurodegenerative conditions.
Prior to Axial, Bridget held the position of Vice President at Flatley Discovery Lab, where she led discovery programs intended to develop and advance compounds for the treatment of cystic fibrosis, including phase 2 clinical candidates, FDL169 and FDL176. Before joining Flatley, she held positions as Vice President at Surface Logix, Associate Director of Chemistry at the Pfizer Research Technology Center and Project Leader in the Pfizer Veterinary Medicine Division.
Bridget holds a B.S. in Chemistry from Boston University and a Ph.D. in Organic Chemistry from Brandeis University.
Current role